Oestrogenic treatment of prostatic cancer lowers the fibrinolytic activity in vein walls.
D000510:Alpha-Globulins / Q000378:metabolism; D000933:Antifibrinolytic Agents / Q000097:blood; D001777:Blood Coagulation / Q000187:drug effects*; D001779:Blood Coagulation Factors; D003864:Depression, Chemical; D004967:Estrogens / Q000494:pharmacology / Q000627:therapeutic use*; D005337:Fibrin / Q000378:metabolism; D005340:Fibrinogen / Q000378:metabolism; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D008259:Macroglobulins; D008297:Male; D010958:Plasminogen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D013997:Time Factors; D014680:Veins / Q000187:drug effects*
D000510:Alpha-Globulins; D000933:Antifibrinolytic Agents; D001779:Blood Coagulation Factors; D004967:Estrogens; D008259:Macroglobulins; D005337:Fibrin; D005340:Fibrinogen; D010958:Plasminogen